Medytox Announces Special Meeting of Its Stockholders to Be

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Medytox Announces Special Meeting of Its Stockholders to Be Held October 28, 2015

WEST PALM BEACH, FL--(Marketwired - Sep 24, 2015) -   Medytox Solutions, Inc. (MMMS) ("Medytox") today announced that the registration statement on Form S-4 filed by CollabRx, Inc. (CLRX) ("CollabRx"), and the definitive joint proxy statement/prospectus contained therein, regarding Medytox's proposed merger with CollabRx, has been declared effective by the Securities and Exchange Commission (the "SEC").

Medytox will hold a special meeting of its stockholders on Wednesday, October 28, 2015, to:

(1) approve and adopt the Agreement and Plan of Merger, dated as of April 15, 2015, by and among CollabRx, CollabRx Merger Sub, Inc., a direct wholly owned subsidiary of CollabRx formed for the purpose of the merger ("Merger Sub"), and Medytox (the "Merger Agreement"), pursuant to which Medytox will become a wholly owned subsidiary of CollabRx, and the transactions contemplated by such agreement.

(2) approve any motion to adjourn the special meeting, or any adjournment thereof, to another time or place if necessary or appropriate to solicit additional proxies if there are insufficient votes at the time of the special meeting to approve and adopt the Merger Agreement and the transactions contemplated thereby.

Medytox's special meeting will be held at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) at the offices of Akerman LLP, located at 777 South Flagler Drive, Suite 100 West Tower, West Palm Beach, Florida 33401. The record date for determination of stockholders entitled to vote at the special meeting is set as of the close of business on September 4, 2015.

Medytox's board of directors unanimously recommends that Medytox stockholders vote "FOR" the proposal to approve and adopt the Merger Agreement, which is necessary to complete the merger; and "FOR" the proposal to approve the adjournment of the Medytox special meeting to a later date or dates, if necessary or appropriate, to permit further solicitation of proxies.

If the merger is completed, Merger Sub will merge with and into Medytox and the separate corporate existence of Merger Sub will cease. Medytox will be the surviving company in the merger, and CollabRx will continue to be the sole stockholder of the surviving company. After the merger, CollabRx and its consolidated subsidiaries, including the surviving company and its subsidiaries, will operate as a combined company under the name Rennova Health, Inc.

Participants in Solicitation Medytox, CollabRx, and their respective directors, executive officers, and other employees may be deemed to be participants in the solicitation of proxies from Medytox and CollabRx stockholders with respect to the merger. Information about Medytox's directors and executive officers is available in Medytox's proxy statement for its Annual Meeting of Stockholders held on August 6, 2015. Information about CollabRx's directors and executive officers is available in CollabRx's annual report on Form 10-K for the fiscal year ended March 31, 2015. Additional information about the interests of potential participants is included in the registration statement and proxy statement and other materials filed with the SEC. These documents are available free of charge at the SEC's website at www.sec.gov , or by going to Medytox's Investors page on its corporate website at www.medytoxsolutionsinc.com or by going to CollabRx's Investors page on its corporate website at www.collabrx.com .

Additional Information This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. CollabRx has filed a registration statement on Form S-4, including a joint proxy statement of CollabRx and Medytox, and other materials with the SEC in connection with the Merger. We urge investors to read these documents because they contain important information. Investors may obtain free copies of the registration statement and proxy statement, as well as other filed documents containing information about Medytox and CollabRx, at www.sec.gov , the SEC's website, or by going to Medytox's Investors page on its corporate website at www.medytoxsolutionsinc.com  or by going to CollabRx's Investors page on its corporate website at www.collabrx.com .

About Medytox Solutions, Inc. Medytox Solutions, Inc. ( OTCQB : MMMS ) is a holding company that owns and operates businesses in the medical services sector. Medytox is a new generation healthcare enterprise that delivers a single source for integrated solutions. Medytox applies its innovative approach through an outstanding suite of IT & software solutions, revenue cycle management and financial services, combined with a range of diagnostic testing and other ancillary services for the healthcare sector. Its principal line of business is clinical laboratory blood and urine testing services, with a particular emphasis in the provision of urine drug toxicology testing to physicians, clinics and rehabilitation facilities in the United States. More information may be obtained at http://www.medytoxsolutionsinc.com .

Safe Harbor Statement This press release contains certain forward-looking information about Medytox Solutions, Inc. that is intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "guidance", "expect", "will", "may", "anticipate", "plan", "estimate", "project", "intend", "should", "can", "likely", "could", and similar expressions are intended to identify forward looking statements. These statements include statements about our plans, strategies and prospects. Forward-looking statements are not guarantees of performance. These statements are based upon the current beliefs and expectations of our management and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot assure you that the expectations will prove to be correct. Important factors that could cause our actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission, which filings are available on www.sec.gov . You should not place undue reliance on these forward-looking statements, which speak only as of the date such statements are made. Except to the extent required by applicable law or regulation, we undertake no obligation to update or publish revised forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events. The potential business combination referenced in this press release is subject to, among other things, stockholder approvals and other customary conditions. We cannot assure you that the contemplated business combination will be consummated.

CollabRx Contacts: Thomas R. Mika President & CEO CollabRx, Inc. 415-248-5350 Medytox Solutions Contacts: Seamus Lagan CEO Medytox Solutions, Inc. 561-855-1626 Sebastien Sainsbury Director, Investor Relations Medytox Solutions, Inc. 561-666-9818 Email Contact Marilys Caraballo - Media Email Contact 305-668-0070 Media Contact: Meieli Sawyer (305) 668-0070 Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 407

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 119

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
Luca's Campo Morado Denial Makes Guerrero Risk Clear

Updated Category News Views 94

A Dangerous Headline Needs More Than a Quick Rebuttal One ugly allegation can do more damage to a junior miner than a lousy quarter, especially when it involves a mine in Guerrero State and alleged criminal control. Luca Mining has flatly rejected Mexican media reports claiming that its Campo Morado Mine is controlled by a criminal organization. The company says the...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 292

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 481

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 75

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 570

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 478

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 91

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 130

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading

Top 5 Most Recently Viewed Articles

Trump Ventures into Cryptocurrency: A Challenging Transition

Updated Category News Views 79

Trump's Shift Towards Cryptocurrency In an unexpected move, Donald Trump has made headlines by stepping into the cryptocurrency market. This shift has drawn both curiosity and skepticism, especially since Trump had previously labeled Bitcoin as a "scam." Many are now questioning if he truly understands the intricacies of the cryptocurrency world he now supports. World...

Continue Reading
IPG Photonics Announces Upcoming Financial Results Event

Updated Category News Views 147

IPG Photonics Scheduled to Release Third Quarter Results IPG Photonics Corporation (Nasdaq: IPGP) is poised to announce its third quarter financial results on November 4, 2025. This event is anticipated to shed light on the Company’s performance and future outlook. Before the market opens that day, IPG will share its financial results, providing investors and...

Continue Reading
Willdan Group Achieves Significant Growth with New Projects

Updated Category News Views 49

Willdan Group Soars to New Heights Willdan Group Inc. (NASDAQ: WLDN) recently celebrated a remarkable achievement as its stock soared to a 52-week high of $41.58. This milestone is not just a number; it represents the confidence that investors have in the company, showcasing a tremendous 109.11% increase in its stock price over the last year. Such significant growth...

Continue Reading
International Paper's Commitment to Shareholders Deepens with Dividends

Updated Category News Views 108

International Paper's Quarterly Dividend Announcement International Paper (NYSE: IP) has reaffirmed its dedication to its shareholders with the announcement of substantial quarterly dividends. Recently, the company declared a dividend of $0.4625 per share, covering the period from the start of January to the end of March of this year. This payment reflects the...

Continue Reading